Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 384, Issue 6, 2011, Pages 505-515

  Di Stefano, Andrea Francesco Daniele ^a   Rusca, Antonio ^a  

^a Cross Research SA   (Switzerland)

Author keywords

MAO B; Parkinson's; Safety; Safinamide; Tyramine

Indexed keywords

SAFINAMIDE; TYRAMINE;

ADJUSTMENT DISORDER; ADULT; ARTHRALGIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HEADACHE; HEARTBURN; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRESSOR RESPONSE; REVIEW; SCREENING TEST; STEADY STATE; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TELEMETRY; VOMITING;

ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; ALANINE; BENZYLAMINES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; TYRAMINE;

EID: 83555164955     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0674-2     Document Type: Review

References (51)

1. C Audebert O Blin S Monjanel-Mouterde P Auquier AM Pedarriosse J Dingemanse A Durand JP Cano 1992 Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers Eur J Clin Pharmacol 43 507 512 1483487 10.1007/BF02285092 1:CAS:528:DyaK3sXltFyqsg%3D%3D
2. J Axelrod G Hertting L Potter 1962 Effect of drugs on the uptake and release of 3H-norepinephrine in the rat heart Nature 194 297 13863455 10.1038/194297a0 1:CAS:528:DyaF38XktFeksLc%3D
3. GB Baker DF LeGatt RT Coutts 1982 A gas chromatographic procedure for quantification of para-tyramine in rat brain J Neurosci Methods 5 181 188 7057679 10.1016/0165-0270(82)90066-8 1:CAS:528:DyaL38XhslOiu78%3D (Pubitemid 12183156)
4. PR Bieck KH Antonin 1989 Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors J Neural Transm Suppl 28 21 31 2794993 1:STN:280:DyaK3c%2FhtFSjsQ%3D%3D
5. HO Borbe G Niebch B Nickel 1990 Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat J Neural Transm Suppl 32 131 137 2128496 1:CAS:528:DyaK38Xlt1Cgurk%3D
6. Borgohain R, Szasz J, Bhatt M, Rossetti S, Lucini V, Anand R (2009) Efficacy and safety of safinamide in patients with Parkinson's disease experiencing motor fluctuations: results of a 6-month Phase III, randomized, double-blind, placebo-controlled study. 13th International Congress of the Movement Disorder Society, Paris, France, 7-11 June 2009. http://www. movementdisorders.org/congress/congress09/late-breaking-abstracts.pdf. Accessed 13 Jan 2009
7. AA Boulton 1978 The tyramines: functionally significant biogenic amines or metabolic accidents? Life Sci 23 659 671 357877 10.1016/0024-3205(78)90064-4 1:CAS:528:DyaE1cXlslKrsrs%3D (Pubitemid 9007780)
8. AA Boulton LE Dyck 1974 Biosynthesis and excretion of meta and para tyramine in the rat Life Sci 14 2497 2506 4549972 10.1016/0024-3205(74)90146-5 1:CAS:528:DyaE2MXntVOhtg%3D%3D
9. JH Burn MJ Rand 1958 The action of sympathomimetic amines in animals treated with reserpine J Physiol 144 314 336 13611696 1:CAS:528: DyaG1MXlt1GjsQ%3D%3D
10. C Caccia R Maj M Calabresi S Maestroni L Faravelli L Curatolo P Salvati RG Fariello 2006 Safinamide: from molecular targets to a new anti-Parkinson drug Neurology 67 S18 S23 17030736 10.1212/01.wnl.0000223846.76431.c1 1:CAS:528:DC%2BD28XhtVeqsLfL (Pubitemid 44568830)
11. C Caccia P Salvati S Rossetti R Anand 2007 Safinamide: beyond MAO-B inhibition Parkinsonism Relat Disord 13 Suppl 2 S99 10.1016/S1353-8020(08)70618- 7
12. C Cattaneo C Caccia A Marzo R Maj RG Fariello 2003 Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition Clin Neuropharmacol 26 213 217 12897643 10.1097/00002826-200307000-00012 1:CAS:528:DC%2BD3sXlvFars7k%3D (Pubitemid 36951068)
13. KR Chaudhuri AH Schapira 2009 Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol 8 464 474 19375664 10.1016/S1474-4422(09)70068-7 1:CAS:528:DC%2BD1MXlsVajsb0%3D
14. PL Chazot 2007 Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome Curr Opin Investig Drugs 8 570 579 17659477 1:CAS:528:DC%2BD2sXpt1Kns7g%3D (Pubitemid 47016325)
15. M Da Prada G Zurcher I Wuthrich WE Haefely 1988 On tyramine, food, beverages and the reversible MAO inhibitor moclobemide J Neural Transm Suppl 26 31 56 3283290
16. M Da Prada R Kettler HH Keller AM Cesura JG Richards J Saura Marti D Muggli-Maniglio PC Wyss E Kyburz R Imhof 1990 From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors J Neural Transm Suppl 29 279 292 2193111
17. E De Leonibus F Manago F Giordani F Petrosino S Lopez A Oliverio M Amalric A Mele 2009 Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease Neuropsychopharmacology 34 729 738 18704096 10.1038/npp.2008.129
18. J Dingemanse Y Hussain A Korn 1996 Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide Int J Clin Pharmacol Ther 34 172 177 8861736 1:CAS:528:DyaK28XivFams7Y%3D (Pubitemid 26109237)
19. RG Fariello 2007 Safinamide Neurotherapeutics 4 110 116 17199024 10.1016/j.nurt.2006.11.011 1:CAS:528:DC%2BD2sXisFaksb4%3D (Pubitemid 46127463)
20. JP Finberg MB Youdim 1985 Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat Br J Pharmacol 85 541 546 3928010 1:CAS:528:DyaL2MXkvVWls7Y%3D (Pubitemid 16244056)
21. T Goren L Adar N Sasson YM Weiss 2010 Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline J Clin Pharmacol 50 1420 1428 20445015 10.1177/0091270010369674 1:CAS:528:DC%2BC3cXhsFyqs7bF
22. W Haefely A Huerlimann H Thoenen 1963 The responses to tyramine of the normal and denervated nictitating membrane of the cat: analysis of the mechanisms and sites of action Br J Pharmacol Chemother 21 27 38 14066148 1:CAS:528:DyaF3sXksVChsrk%3D
23. ICH (2002) Harmonised Tripartite Guidelines for Good Clinical Practice. ICH Topic E6, CPMP/ICH/135/95.
24. Juorio AV, Greenshaw AJ, Boulton AA (1985) Possible pathways for some trace amine-containing neurons. In: Boulton AA, Maitre L, Bieck PR, Rieder P (eds) Neuropharmacology of trace amines. Humana, Clifton, pp 87-99
25. Karoum F (1983) Mass fragmentography in the analysis of biogenic amines: a clinical, physiological and pharmacological evaluation. In: Nagatsu S, Nagatsu T, Pravez H (eds) Methods in biogenic amine research. Elsevier, New York, pp 237-255
26. F Karoum 1985 On the origin of central and peripheral p-hydroxy-phenylacetic acid in rats: a comparison with metabolites of biogenic amines other than p-tyramine Biogenic Amines 2 269 282 1:CAS:528: DyaL2MXltFKrt7c%3D
27. A Korn M Da Prada W Raffesberg S Gasic HG Eichler 1988 Effect of moclobemide, a new reversible monoamine oxidase inhibitor on absorption and pressor effect of tyramine J Cardiovasc Pharmacol 11 17 23 2450251 10.1097/00005344-198801000-00003 1:CAS:528:DyaL1cXoslKjtw%3D%3D (Pubitemid 18020871)
28. AJ Lees KM Shaw LJ Kohout GM Stern JD Elsworth M Sandler MB Youdim 1977 Deprenyl in Parkinson's disease Lancet 2 791 795 71602 10.1016/S0140-6736(77) 90725-5 1:STN:280:DyaE1c%2FgvFChtw%3D%3D (Pubitemid 8193248)
29. PA LeWitt 2009 Levodopa therapeutics for Parkinson's disease: new developments Parkinsonism Relat Disord 15 Suppl 1 S31 S34 19131040 10.1016/S1353-8020(09)70009-4
30. A Marzo L Dal Bo NC Monti F Crivelli S Ismaili C Caccia C Cattaneo RG Fariello 2004 Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity Pharmacol Res 50 77 85 15082032 10.1016/j.phrs.2003.12.004 1:CAS:528:DC%2BD2cXjtVCgs7w%3D (Pubitemid 38479671)
31. A Patat I Berlin G Durrieu P Armand S Fitoussi P Molinier P Caille 1995 Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects J Clin Pharmacol 35 633 643 7665725 1:CAS:528:DyaK2MXmvFCgtLs%3D
32. P Pevarello A Bonsignori P Dostert F Heidempergher V Pinciroli M Colombo RA McArthur P Salvati C Post RG Fariello M Varasi 1998 Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives J Med Chem 41 579 590 9484507 10.1021/jm970599m 1:CAS:528: DyaK1cXms1Oitw%3D%3D (Pubitemid 28093092)
33. P Salvati R Maj C Caccia MA Cervini MG Fornaretto E Lamberti P Pevarello GA Skeen HS White HH Wolf L Faravelli M Mazzanti E Mancinelli M Varasi RG Fariello 1999 Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound J Pharmacol Exp Ther 288 1151 1159 10027853 1:CAS:528:DyaK1MXhs1Kisr8%3D (Pubitemid 29254153)
34. M Sandler V Glover A Ashford GM Stern 1978 Absence of "cheese effect" during deprenyl therapy: some recent studies J Neural Transm 43 209 215 745013 10.1007/BF01246957 1:STN:280:DyaE1M7jtFOnsA%3D%3D (Pubitemid 9050081)
35. AH Schapira 2007 Treatment options in the modern management of Parkinson disease Arch Neurol 64 1083 1088 17698697 10.1001/archneur.64.8.1083 (Pubitemid 47258065)
36. HJ Shuemann A Philippu 1962 Release of catechol amines from isolated medullary granules by sympathomimetic amines Nature 193 890 891 13912355 10.1038/193890a0 1:STN:280:DyaF387gtl2ntQ%3D%3D
37. KI Shulman SE Walker S MacKenzie S Knowles 1989 Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors J Clin Psychopharmacol 9 397 402 2592589 10.1097/00004714-198912000-00002 1:STN:280: DyaK3c%2FnvVOjtw%3D%3D (Pubitemid 20023019)
38. F Stocchi G Arnold M Onofrj H Kwiecinski A Szczudlik A Thomas U Bonuccelli A Van Dijk C Cattaneo P Sala RG Fariello 2004 Improvement of motor function in early Parkinson disease by safinamide Neurology 63 746 748 15326260 1:CAS:528:DC%2BD2cXmtlSjsbs%3D (Pubitemid 39100843)
39. Stocchi F, Borgohain R, Onofrj M, Shapiro A, Bhatt M, Lorenzana P, Rossetti S, Anand R (2007) Safinamide, a new anti-parkinson agent is effective and well-tolerated in early PD patients on a stable dose of single DA-agonist: results of a randomized, international, placebo-controlled Phase II trial. Poster presented at the American Academy of Neurology 59th Annual Meeting, Boston, USA, 1 May 2007
40. MS Strolin Benedetti P Marrari M Colombo MG Castelli M Arand F Oesch P Dostert 1994 The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats J Pharm Pharmacol 46 814 819 7699569 10.1111/j.2042-7158.1994.tb03736.x 1:STN:280:DyaK2M3htl2huw%3D%3D (Pubitemid 24319166)
41. M Tacker WM McIsaac PJ Creaven 1970 Metabolism of tyramine-1-14 C by the rat Biochem Pharmacol 19 2763 2773 5478585 10.1016/0006-2952(70)90103-6 1:CAS:528:DyaE3MXhtFSnuw%3D%3D
42. F Vaghi R Maj G Ukmar G Lamberti RA McArthur M Varasi P Salvati C Post 2007 Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils Soc Neurosci Abstr 23 545
43. US von Euler F Lishajko 1960 Release of noradrenaline from adrenergic transmitter granules by tyramine Experientia 16 376 377 10.1007/BF02157916
44. SE Walker KI Shulman SA Tailor D Gardner 1996 Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets J Clin Psychopharmacol 16 383 388 8889911 10.1097/00004714-199610000-00007 1:STN:280:DyaK2s%2FksVynsg%3D%3D (Pubitemid 26352668)
45. M Yamada H Yasuhara 2004 Clinical pharmacology of MAO inhibitors: safety and future Neurotoxicology 25 215 221 14697896 10.1016/S0161-813X(03)00097-4 1:CAS:528:DC%2BD3sXhtVSjtLvI (Pubitemid 38044183)
46. Youdim MB (1977) Tyramine in psychiatric disorders. In: Usdin E, Homburg D, Barchas JD (eds) Neuroregulators and psychiatric disorders. Oxford University Press, Oxford, UK, pp 57-67
47. MB Youdim 1990 Monoamine oxidase (MAO)-A but not MAO-B inhibitors potentiate tyramine-induced catecholamine release from PC12 cells J Neurochem 54 411 414 2299343 10.1111/j.1471-4159.1990.tb01888.x 1:CAS:528: DyaK3cXptFOlug%3D%3D (Pubitemid 20044288)
48. MB Youdim M Weinstock 2004 Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation Neurotoxicology 25 243 250 14697899 10.1016/S0161-813X(03)00103-7 1:CAS:528:DC%2BD3sXhtVSjtLjM (Pubitemid 38044185)
49. Youdim MB, Bakhle YS, Ben-Harari RR (1979) Comparison of monoamine oxidase activity in perfused organs in vitro. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: structure, function and altered functions. Academic, New York, pp 361-377
50. MB Youdim A Gross JP Finberg 2001 Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Br J Pharmacol 132 500 506 11159700 10.1038/sj.bjp.0703826 1:CAS:528:DC%2BD3MXht1Sgu7o%3D (Pubitemid 32142364)
51. Zar J (1984) Biostatistical analysis. Prentice-Hall, Upper Saddle River